Fig.3
One-way sensitivity analysis of sorafenib versus sintilimab-bevacizumab (INMBs) disc_rate discount rate, HFSR hand-foot skin reaction, INMB incremental net monetary benefits, NMB net monetary benefits, PartSA partitioned survival analysis, PD progressive disease, PF progression free